Breaking Down CGN Nuclear Technology Development Co., Ltd. Financial Health: Key Insights for Investors

CGN Nuclear Technology Development Co., Ltd. (000881.SZ) presents a mixed financial picture that demands investor attention: Q3 2025 revenue fell to CNY 1.472 billion (down 9.72% sequentially) and TTM revenue sits at CNY 5.78 billion (down 7.81% YoY) after 2024 annual revenue of CNY 6.17 billion (a 2.90% decline vs. 2023), while profitability strains are clear with a H1 2025 net loss attributable to shareholders of CNY 99.82 million, a basic loss per share of CNY 0.1056 and a net profit margin of -3.85%; balance sheet and leverage show total debt CNY 3.0 billion against cash of CNY 1.544 billion (debt/equity 0.60) and an interest coverage ratio of -3.06 even as liquidity metrics remain serviceable (current ratio 1.88, quick ratio 1.38, operating cash flow CNY 456 million), valuation sits at P/S 1.46 and P/B 1.42 with market cap around CNY 8.43 billion (share price CNY 8.92 as of Dec 4, 2025), and growth vectors include a 30% YoY jump in electronic accelerator sales in 2024, 18 irradiation centers with 62 accelerators in operation, the home-grown S-band 10MeV/32kW accelerator milestone and 14 accelerators exported to the EU-read on for the full, number-by-number analysis to gauge whether the company's niche technology momentum can offset its revenue decline and profitability headwinds.

CGN Nuclear Technology Development Co., Ltd. (000881.SZ) - Revenue Analysis

• Quarterly volatility: Q3 2025 revenue fell 9.72% from Q2 2025, a notable single-quarter decline.
• Year-over-year pressure: TTM revenue down 7.81% YoY; 2024 revenue down 2.90% vs 2023.
• Productivity: Revenue per employee CNY 1.33M with 4,338 headcount-moderate productivity for capital-intensive tech.
• Valuation context: P/S of 1.46 and market cap CNY 8.43B imply a modest market valuation relative to sales.
• Growth gap: Company revenue down 9.6% over three years while the industry expects ~22% growth next year, indicating relative underperformance.

CGN Nuclear Technology Development Co., Ltd. (000881.SZ) - Profitability Metrics

Key profitability indicators for CGN Nuclear Technology Development Co., Ltd. show sustained weakness through H1 2025 and across the last five years, with losses, declining operating profit and negative returns to shareholders.

• Net loss attributable to shareholders (H1 2025): CNY 99.82 million (versus a loss of CNY 86.58 million in H1 2024).
• Basic loss per share (H1 2025): CNY 0.1056 (H1 2024: CNY 0.0916).
• Net profit margin (H1 2025): -3.85%.
• Return on equity (ROE): -6.47%.
• Five-year earnings growth: average annual decline of 63.9% (chemicals industry benchmark: -1.7% annually).
• Five-year operating profit change: -287.55% (indicative of cumulative deterioration and occasional large negative periods).

Investor-focused implications to consider include liquidity strain from continued losses, dilution risk if equity raises are needed, and structural or market drivers behind the steep multi-year earnings decline. For broader company context and background, see CGN Nuclear Technology Development Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money.

CGN Nuclear Technology Development Co., Ltd. (000881.SZ) - Debt vs. Equity Structure

CGN Nuclear Technology Development Co., Ltd. (000881.SZ) displays a capital structure characterized by meaningful leverage combined with constrained earnings capacity. Key headline metrics frame the core issues:

• Debt-to-equity ratio: 0.60, reflecting a moderate debt load relative to equity.
• Total debt: CNY 3.0 billion; cash reserves: CNY 1.5 billion - debt exceeds cash by CNY 1.5 billion.
• Interest coverage ratio: -3.06, indicating operating earnings are insufficient to cover interest expense.
• Enterprise value (EV): CNY 9.95 billion; market capitalization: CNY 7.79 billion - EV exceeds market cap, signaling net debt contribution to firm value.
• Total liabilities have trended upward in recent years, elevating refinancing and liquidity risk.

The following table summarizes the principal balance-sheet and market metrics cited above for quick reference:

Trend in total liabilities (illustrative recent annual series):

• Negative interest coverage (-3.06) signals that operating income is insufficient to service interest - this can force reliance on cash, asset sales, or new financing to meet obligations.
• EV > market cap (CNY 9.95B vs. CNY 7.79B) highlights net debt's material contribution to enterprise value; equity holders face greater downside if liabilities rise further.
• Rising total liabilities over multiple years increases refinancing needs and reduces financial flexibility, particularly given limited cash buffers (CNY 1.5B) versus debt (CNY 3.0B).

For broader context on the company's background and operational model, see: CGN Nuclear Technology Development Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

CGN Nuclear Technology Development Co., Ltd. (000881.SZ) - Liquidity and Solvency

CGN Nuclear Technology Development Co., Ltd. (000881.SZ) exhibits a generally healthy short-term liquidity profile while facing profitability challenges that affect long-term solvency metrics.

• Current ratio: 1.88 - sufficient short-term assets to cover short-term liabilities.
• Quick ratio: 1.38 - indicates ability to meet short-term obligations without relying on inventory.
• Cash and cash equivalents: CNY 1.544 billion - a meaningful liquidity buffer for operations and debt servicing.
• Operating cash flow (most recent fiscal period): CNY 456 million - positive cash generation from core operations.
• Reported net losses in the latest periods - cash-generative operations have not yet translated into positive net income.
• Liquidity position has been stable over recent years with only minor fluctuations in cash reserves and current ratio.

Key considerations for investors:

• Positive operating cash flow (CNY 456m) supports near-term obligations and capital needs despite net losses.
• Cash cushion (CNY 1.544bn) reduces refinancing risk but must be monitored alongside capital expenditure and debt maturities.
• Stable current and quick ratios indicate consistent short-term liquidity; however, recurring net losses highlight the need to assess path to sustained profitability.

For broader context on company background and how it generates revenue, see CGN Nuclear Technology Development Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

CGN Nuclear Technology Development Co., Ltd. (000881.SZ) Valuation Analysis

• Share price (Dec 4, 2025): CNY 8.92
• Market capitalization: CNY 8.43 billion
• Enterprise value (EV): CNY 9.95 billion
• Price-to-Sales (P/S): 1.46
• Price-to-Book (P/B): 1.42
• Dividend policy: no dividend payments (cash preservation prioritized)

• The P/S of 1.46 positions the company below many industry peers, suggesting either undervaluation or market concern about revenue sustainability and margins.
• The P/B of 1.42 indicates the market places a modest premium over reported book value-consistent with industrial-sector norms but not signaling strong growth expectations.
• EV (CNY 9.95B) exceeding market cap (CNY 8.43B) implies net debt; investors should examine leverage, interest coverage, and maturities to assess refinancing and risk.
• Absence of dividends points to cash preservation priorities-likely a response to capital expenditure needs, debt service, or operational conservatism.
• Overall valuation metrics being below industry averages may create a value opportunity if operational and balance-sheet risks are resolved; conversely, they may reflect legitimate investor concerns about future earnings and cash flow.

CGN Nuclear Technology Development Co., Ltd. (000881.SZ) - Risk Factors

• Recent profitability deterioration: reported net loss of CNY 99.82 million in H1 2025, continuing a trend of negative net income in recent reporting periods.
• Leverage profile: debt-to-equity ratio of 0.60, indicating a moderate debt load that increases financial vulnerability if cash flows weaken.
• Interest coverage stress: negative interest coverage ratio of -3.06, showing operating earnings are insufficient to cover interest expenses and signaling potential liquidity strain.
• Revenue trajectory: revenue has declined 9.6% over the past three years, underperforming against industry momentum (industry projected growth ~22% next year), suggesting possible market-share erosion.
• Operating profitability collapse: operating profit has decreased by 287.55% over the last five years, reflecting either recurring operating losses or large one-off adjustments that materially impair core profitability.
• Capital return policy: absence of dividend payments in recent periods, which may indicate retention of cash to shore up the balance sheet or an inability to distribute earnings to shareholders.

• Cash-flow sensitivity: with negative interest coverage and recent losses, the company is sensitive to margin compression, contract delays, or increases in borrowing costs.
• Refinancing and covenant risk: moderate leverage combined with weak earnings raises the probability of covenant breaches or more costly refinancing terms if markets tighten.
• Competitive and market risk: a revenue decline of 9.6% over three years versus an industry growth outlook of 22% suggests CGN Nuclear Technology Development may be losing competitive ground or facing demand shifts.
• Investor sentiment risk: absence of dividends and large declines in operating profit can erode investor confidence and depress valuation multiples, limiting access to equity capital on favorable terms.

CGN Nuclear Technology Development Co., Ltd. (000881.SZ) - Growth Opportunities

• Electronic accelerator business: reported a 30% year-over-year sales increase in 2024, driven by higher demand for irradiation processing and industrial applications.
• R&D leadership: completed China's first S-band 10MeV/32kW high-power industrial irradiated electron accelerator, positioning the company at the forefront of a high-value niche.
• Business diversification: strategic moves into nuclear medical applications and transformation of traditional new materials operations create potential new revenue streams.
• Service footprint: 18 irradiation centers and 62 electron accelerators in operation across China provide a scalable platform for irradiation processing services and client expansion.
• Policy tailwinds: focus on non-powered nuclear technology applications benefits from favorable industry policies promoting irradiation, sterilization and materials processing.
• International expansion: exported 14 accelerators to the EU in 2024, signaling initial traction for overseas revenue diversification.

• Commercial implications: the 62-unit domestic installed base reduces incremental customer acquisition cost for irradiation services, while 18 centers allow scaling utilization rates and margin improvement.
• Margin levers: higher-value equipment (e.g., 10MeV/32kW S-band accelerators) and service contracts (sterilization, polymer modification, food irradiation) can raise gross margins versus commodity equipment sales.
• International upside: 14 EU exports in 2024 demonstrate product compliance and market acceptance; further EU and APAC penetration could buffer domestic cyclical risk.
• Policy and non-powered nuclear focus: supportive regulation and subsidies for non-powered nuclear tech accelerate adoption in industrial, medical and materials markets.